Strategic Blueprint LLC Takes $617,000 Position in Boston Scientific Corporation $BSX

Strategic Blueprint LLC purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 6,323 shares of the medical equipment provider’s stock, valued at approximately $617,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares during the period. State Street Corp raised its stake in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Geode Capital Management LLC lifted its position in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank purchased a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. grew its position in Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after buying an additional 226,578 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Evercore ISI set a $112.00 price objective on shares of Boston Scientific in a research report on Monday. Barclays increased their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Morgan Stanley raised their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Royal Bank Of Canada raised their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $125.21.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,095 shares of company stock valued at $9,305,450 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $97.68 on Friday. The business has a 50 day moving average price of $97.58 and a 200 day moving average price of $100.78. The company has a market capitalization of $144.80 billion, a P/E ratio of 52.23, a PEG ratio of 1.74 and a beta of 0.67. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.